Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Astex Therapeutics

Alternative Names: AT 9311; AT1772; AT2035; AT3424; AT381; AT3851; LCQ 195; NVP-LCQ195

Latest Information Update: 25 Jul 2011

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Class Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Dec 2005 AT 9311 has been licensed to Novartis worldwide
  • 12 Sep 2005 AT 7519 has advanced from this programme into clinical development
  • 29 Nov 2004 Data presented at the British Cancer Research Meeting 2004 (BCRM 2004) have been added to the pharmacokinetics and Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top